Other Events ·
On July 20, 2026, Oncolytics Biotech Inc. received notification from Nasdaq that its common stock failed to meet the…
ONCYOncolytics Biotech Inc
On July 20, 2026, Oncolytics Biotech Inc. received notification from Nasdaq that its common stock failed to meet the $1.00 minimum bid price requirement after closing below that level for 30 consecutive business days. The company has a compliance period until January 19, 2027, to regain compliance by maintaining a closing bid price of at least $1.00 for ten consecutive business days. Failure to regain compliance may lead to delisting, although an additional 180-day extension may be available if certain criteria are met. The company is currently assessing options to maintain its listing. This company is a biotechnology firm that develops immunotherapies for the treatment of cancer.